J. Vidal, F. Bacin, and E. Albuisson, Melanoma 92 " . Epidemiological study of uveal melanomainFrance, p.520528, 1995.

J. Scotto, J. Fraumeni, and J. Lee, Melanomas of the eye and other noncutaneous sites : epidemiologicaspects, p.489491, 1976.

. Chardh, . Quiveyjm, and K. Castrojr, Heliumionsversusiodine125brachytherapyinthe managementofuvealmelanoma.Aprospective,randomized,dynamicallybalancedtrial, p.15471554, 1993.

. Caujollejp, . Maschic, . Fretona, . Pagesg, and . Gastaudp, Treatmentofneovascularglaucomaafter proton therapy for uveal melanomas with ranibizumab injection : preliminary results, p.5760, 2012.

. Rosenfeldpj, . Schwartzsd, and . Blumenkranzms, Maximumtolerateddoseofahumanizer antivascular endothelial growth factor antibody fragment for treating neovascular age ? relatedmaculardegeneration, Ophtalmology, vol.112, p.10481053, 2005.

. Amicodj, . Masonsonhn, . Patelm, . Adamisap, . Cunninghametjr et al., VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Pegaptanib sodiumforneovascularagerelatedmaculardegeneration:twoyearsafetyresultsofthetwo prospective,multicenter,controlledclinicaltrials, p.9921001, 2006.

. Browndm, . Kaiserpk, . Michelsm, . Soubraneg, . Heierjs et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration, p.143244, 2006.

Q. Nguyen, S. Shah, and A. Khwaja, Twoyear outcomes of the ranibizumab for edema of the macula in diabetes (READ2) study, Ophthalmology, vol.117, p.214651, 2010.

S. Nghiembuffet and S. Cohen, Retinalveinocclusion: antiVEGF treatments, J Fr Ophtalmol, vol.32, issue.9, p.67986, 2009.

. Paezribes, Antiangiogenic therapy elicits malignant progression of tumors to increasedlocalinvasionanddistantmetastasis, p.220231, 2009.

J. Caujolle, H. Mammar, E. Chamorey, F. Pinon, J. Herault et al., Proton Beam Radiotherapy for Uveal Melanomas at Nice Teaching Hospital: 16 Years' Experience, International Journal of Radiation Oncology*Biology*Physics, vol.78, issue.1, p.98103, 2010.
DOI : 10.1016/j.ijrobp.2009.07.1688

C. Shields, H. Demici, and M. Materin, Clinical factors in the identification of small choroidalmelanoma, CanJOphthalmol, vol.39, p.351357, 2004.

A. Singh, M. Turell, and A. Topham, Uveal Melanoma: Trends in Incidence, Treatment, and Survival, Ophthalmology, vol.118, issue.9, p.18811885, 2011.
DOI : 10.1016/j.ophtha.2011.01.040

L. Jampol, C. Moy, and T. Murray, The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, Ophthalmology, vol.109, issue.12, p.2197, 2002.
DOI : 10.1016/S0161-6420(02)01277-0

C. Shields, M. Naseripour, and J. Cater, Radiotherapy for large posterior uveal melanoma (>OR=8mmthick)in354consecutivepatients, Ophtalmology, vol.109, p.18381849, 2002.

?. Diener, M. West, J. Earle, and S. Fine, The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma , II : characteristics of patients enrolled and not enrolled, COMSreportno17.ArchOphtalmol, vol.119, issue.7, p.951965, 2001.

S. Seregard, B. Damato, and P. Fleming, Uveal malignant melanoma : management options brachytherapy, ClinicalOphtalmicOncology, p.241247, 2007.
DOI : 10.1016/b978-1-4160-3167-3.50046-2

B. Damato and I. Patel, Visual Acuity after Ruthenium(106) brachytherapy of choroidal melanomas, IntJRadiatOncolBiolPhys, vol.63, issue.2, p.392400, 2005.

A. Russo, M. Laguardia, and B. Damato, Eccentric ruthenium plaque radiotherapy of posterior choroidalmelanoma, GraefesArchclinExpOphtalmol, vol.250, issue.10, p.15331540, 2012.

B. Damato and A. Kacperek, Proton beam radiotherapy of choroidal melanoma : the LiverpoolClatterbridgeexperience, IntJRadiatOncolBiolPhys, vol.62, issue.5, p.14051411, 2005.

. Wangzetal, Chargedparticleradiationtherapyforuvealmelanoma:asystematicreview andmetaanalysis.IntJRadiatOncolBiolPhys, 2012.

E. Gragoudas, W. Li, and M. Goiten, Evidencebased estimates of outcome in patients irradiatedforintraocularmelanoma, ArchOphthalmol, vol.120, issue.12, p.16551671, 2002.

W. Campbell and T. Pejnovic, Treatment of amelanotic choroidal melanoma with photodynamictherapy, Retina, vol.201232, issue.7, p.13561362

. Yarovoyaa, . Magaramovda, and . Bulgakovaes, Thecomparisonofrutheniumbrachytherapyand simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone, Brachytherapy, vol.11, issue.3, p.224229, 2012.

N. Bechrakis, . Petousis-v, and G. Willerding, Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate, British Journal of Ophthalmology, vol.94, issue.4, p.460466, 2010.
DOI : 10.1136/bjo.2009.162487

I. Puusaari, Iodine brachytherpy as an alternative to enucleation for large uveal melanomas, p.22232234, 2003.

E. Gragoudas, A. Lane, J. Munzenrider, K. Egan, and W. Li, Longterm risk of local failure afterprotontherapyforchoroidal/ciliarybodymelanoma, TransAmophtalmolSoc, vol.100, p.4348, 2002.

. Gündüzk, . Shieldsscl, and . Shieldsja, Radiationcomplicationsandtumorcontrolafterplaque radiotherapy of choroidal melanoma with macular involvement, American J Ophthalmol, vol.579589, p.127, 1999.

C. Fingerpt, Y. , and P. , Riskfactorsforradiationmaculopathyafterophthalmic plaqueradiationforchoroidalmelanoma, AmJOphtalmol, vol.149, issue.4, p.608615, 2010.

P. Saconn, C. Gee, C. Greven, T. Mccoy, K. Ekstrand et al., Alternative dose for choroidal melanoma treated with an iodine125 radioactive plaque: A singleinstitution retrospectivestudy, p.844848, 2010.

. Jensenaw, Radiationcomplicationsandtumorcontrolafter125Iplaquebrachytherpy forocularmelanoma.IntJRadiatOncolBiolPhys2005;63:101108 cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative OcularMelanomaStudy:COMSreportno27, Ophtalmology, vol.114, issue.7, p.13631371, 2007.

G. Missotten and I. Notting, Vascular Endothelial Growth Factor A in Eyes With Uveal Melanoma, Archives of Ophthalmology, vol.124, issue.10, p.14281434, 2006.
DOI : 10.1001/archopht.124.10.1428

E. Detorakis, R. Engstrom, . Jr, R. Wallace, and S. Br, Iris and anterior chamber angle neovascularisationafteriodine125brachytherapyforuvealmelanoma, Ophtalmology, vol.112, p.505510, 2005.

. Folkmanj, Tumorangiogenesis:therapeuticimplications, NewEnglandJournalofMedicine, vol.285, p.11821186, 1971.

M. Criscuologr, OldfieldEH:Furthercharacterizationofmalignantglioma?derived vascularpermeabilityfactor, Jneurosurg, vol.69, p.254262, 1988.

A. Karayiannakis, Circulating VEGF Levels in the Serum of Gastric Cancer Patients, Annals of Surgery, vol.236, issue.1, p.3742, 2002.
DOI : 10.1097/00000658-200207000-00007

. Celeno and Y. Kahramani, BerberogluU:correlationofvascularendothelialgrowth factor ( VEGF) and CEA with clinicopathological variables in colorectal cancer patients, Neoplasma, vol.51, p.293299, 2004.

A. Hayes, Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma, British Journal of Surgery, vol.91, issue.2, p.242247, 2004.
DOI : 10.1002/bjs.4398

M. Cobleigh and V. Langmuir, A phase I/II dose ?escalation trial of bevacizumab in previouslytreatedmetastaticbreastcancer, p.117124, 2003.

B. Varkerka, Arandomizedphase2trialofbevacizumabwithorwithoutdailylow dose interferon alpha2bin metastatic malignant melanoma, Ann Surg Oncol, vol.14, 2007.

V. Vance, PhaseIIItrialofbevacizumabincombinationwithgemcitabine anderlotinibinpatientswithmetastaticpancreaticcancer, p.22312237, 2009.

P. Finger and K. Chin, Antivascular endothelial growth factor bevacizumab (avastin ) for radiationretinopathy, ArchOphtalmol, vol.125, p.751756, 2007.

F. Houckka, Thevascularendothelialgrowthfactorfamily:identificationofa fourthmolecularspiciesandcharacterizationofalternativesplicingofRNA, MolEndocrinol, vol.5, p.18061814, 1991.

. Shweikid, . Itina, and . Sofferd, KeshetE:Vascularendothelialgrowthfactorinducedbyhypoxia maymediatehypoxia?initiatedangiogenesis, p.843845, 1992.

H. Takahashi and M. Shibuya, The vascular endothelial growth factor ( VEGF ) / VEGF receptor systemanditsroleunderphysiologicalandpathologicalconditions, ClinSci(Lond), vol.109, p.227241, 2005.

R. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy, Science, vol.307, issue.5706, p.5862, 2005.
DOI : 10.1126/science.1104819

P. Saharinen, VEGF and angiopoietin signalling in tumor angiogenesis and metastasis, TrendsinMolecularMedicine, vol.17, issue.7, p.347362, 2011.

. El-filali, Antiangiogenic therapy in uveal melanoma, Dev Ophtalmol . Basel, Karger, vol.49, p.117136, 2012.

. Landsc, TeeAR:Hypoxia?inductiblefactor1alphaisregulatedbythemammaliantargetof rapamycin(mTOR)signalingmotif, JBiolChem, vol.282, p.2053420543, 2007.

A. Roccaro, Bortezomib mediates antiangiogenesis in multiple myeloma via direct andindirecteffectsonendothelialcells, CancerRes, vol.66, pp.184-191, 2006.

B. Kenyon, F. Browne, D. Amato, and R. , Effects of thalidomide and related metabolites in a mousecornealmodelofneovascularization, ExpeyeRes, vol.64, p.971978, 1997.

V. Witmeran, Vascularendothelialgrowthfactorsandangiogenesisineye disease, ProgRetinEyeRes, vol.22, p.129, 2003.

. Tufaila and . Narendrann, Ranibizumabinmyopicchoroidalneovascularization: the12monthresultsfromtheREPAIRstudy, Ophtalmology, vol.120, issue.9, p.19441945, 2013.

A. Gupta and J. Muecke, Treatment of Radiation Maculopathy With Intravitreal Injection of Bevacizumab (Avastin), Retina, vol.28, issue.7, p.964968, 2008.
DOI : 10.1097/IAE.0b013e3181706302

P. Finger and K. Chin, Intravitreous Ranibizumab (Lucentis) for Radiation Maculopathy, Archives of Ophthalmology, vol.128, issue.2, p.249252, 2010.
DOI : 10.1001/archophthalmol.2009.376

R. Dunavoelgyi, M. Zehetmayer, C. Simader, ?. Schmidt, and U. Erfuth, Rapid improvement of radiation ?induced neovascular glaucoma and exudative retinal detachment after a single intravitrealranibizumabinjection, ClinExperimentOphtalmol, vol.35, p.878880, 2007.

L. Vàsquez, S. Somani, F. Altomare, and E. Simpson, Intracameral bevacizumab in the treatmentofneovascularglaucomaandexudativeretinaldetachmentafterbrachytherapy inchoroidalmelanoma, CanJOphtalmol, vol.44, p.106107, 2009.

N. Frenkels and K. Hendleretal, Longtermsurvivalofuvealmelanomapatientsaftersurgery forlivermetastases, BritishJournalofOphtalmology, vol.93, issue.8, p.10421046, 2009.

R. Kaiserman, J. Amer, and . Peer, Liver function tests in metastatic uveal melanoma, American Journal of Ophthalmology, vol.137, issue.2, p.236243, 2004.
DOI : 10.1016/j.ajo.2003.08.045

S. Callejo, E. Antecka, P. Blanco, C. Edelstein, M. Burnier et al., identification of circulating malignantcellsanditscorrelationwithprognosticfactorsandtreatmentinuvealmelanoma, Aprospectivelongitudinalstudy.Eye(Lond), vol.21, issue.6, p.752759, 2007.

P. Blanco, L. Lim, C. Burnier, and M. , Uveal melanoma dormancy, Melanoma Research, vol.22, issue.5, p.334340, 2012.
DOI : 10.1097/CMR.0b013e328357bea8

D. Croock, L. Verbraeken, and H. , Metastatic uveal melanoma: diagnosis end treatment. A literaturereview, BullSocBelgeOphtalmol, vol.286, p.5963, 2002.

C. Ocular-melanoma-study and . Group, Assessment of metastatic disease status at deathin435patientswithlargechoroidalmelanomaintheCollaborativeOcularMelanoma Study(COMS):COMSreportno15, ArchOphtalmol, vol.119, issue.5, p.670676, 2001.

W. Se, metastatic uveal melanoma : biology and emerging treatments, cancer J, vol.18, issue.2, p.148152, 2012.

. Basergar, TheinsulinlikegrowthfactorIreceptor:akeytotumorgrowth?, CancerRes, vol.55, p.249252, 1995.

H. Shammas and F. Blodi, Prognostic Factors in Choroidal and Ciliary Body Melanomas, Archives of Ophthalmology, vol.95, issue.1, p.6369, 1977.
DOI : 10.1001/archopht.1977.04450010065005

. Laneam and . Egankm, Adjuvantinterferontherapyforpatientswithuvealmelanomaat highriskofmetastasis, Ophtalmology, vol.116, issue.11, p.22062212, 2009.

C. Gomer, Preclinical examination of first and second generation photosensitizers used in photodynamictherapy, Photochemphotobiol, vol.54, issue.6, p.10931107, 1991.

K. Sugihara and H. Uetake, Therapeutic strategies for hepatic metastasis of colorectal cancer: overview, Journal of Hepato-Biliary-Pancreatic Sciences, vol.24, issue.5, p.523527, 2012.
DOI : 10.1007/s00534-012-0524-8

J. Llovet, M. Real, and X. Montana, arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomizedcontrolledtrial, Lancet, vol.359, issue.9319, p.17341739, 2002.

. Satot, . Eschelmandj, and . Gonsalvescf, Immunoembolizationofmalignantlivertumors, includinguvealmelanoma,usinggranulocytemacrophagecolony?stimulatingfactor, JClin oncol, vol.26, issue.33, p.54365442, 2008.

R. Albertdm and . Bordenec, Metastaticocularandcutaneousmelanoma:acomparison ofpatientcharacteristicsandprognosis, ArchOphtalmol, vol.114, issue.1, p.107108, 1996.

F. Pons, M. Plana, and J. Caminal, Metastatic uveal melanoma, Melanoma Research, vol.21, issue.3, p.217222, 2011.
DOI : 10.1097/CMR.0b013e3283457726

. Danielsab, . Leeje, and . Macconaillle, Highthroughputmassspectrometrybasedmutation profilingofprimaryuvealmelanoma, InvestOphtalmolVisSci, vol.53, issue.11, p.69916996, 2012.

E. Kujala and T. Kivela, Tumor , node , metastasis classification of malignant ciliary body and choroidalmelanoma, p.11351144, 2005.

E. Gragoudas, Longterm results after proton irradiation of uveal melanomas, Graefes Arch ClinExpOphthalmolol, vol.35, p.265267, 1997.

. Eggere, . Zografosl, . Schalenbourga, . Beatid, . Böhringert et al., Eyeretention after proton beam radiotherapy for uveal melanoma, Int J Radiation Oncology Biol Phys, vol.55, p.86780, 2003.

L. Desjardins, L. Lumbroso, C. Levy, A. Mazal, S. Delacroix et al., Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparisonoflocalrecurrencerates], JFrOphtalmol, vol.26, issue.3, p.269276, 2003.

. Hamrouniz, . Levyc, D. Lumbrosol, . Hermiesf, . Fraue et al., Resultsoftreatinguveal melanomawithprotonbeamradiation:10yearfollowup], JFrOphtalmol, vol.28, issue.8, p.833, 2005.

M. Wilson and J. Hungerford, Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanomaAfiveyearstudyofslottedeyeplaqueradiationtherapyfor choroidalmelanoma:near,touching,orsurroundingtheopticnerve, Ophthalmology. AoûOphthalmology, vol.106119, issue.82, pp.1579-1587, 1999.

H. Jager, M. Et-grossniklaus, and H. , Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma .Investigative Ophtalmology and visual science, p.28352842, 2010.

A. Daka, A. Susini, L. Nigro, and C. , Combination of bevacizumab and irradiation on uveal melanoma:aninvitroandinvivopreclinicalstudy, InvestNewDrugs, vol.31, p.5965, 2013.

J. Li, The proliferation of malignant melanoma cells could be inhibited by ranibizumabviaantagonizingVEGFthroughVEGFR1 104BagriAetal.Effectsofanti?VEGFtreatmentdurationontumorgrowth,tumorregrowth, andtreatmentefficacy 105DeBockKetal.Antiangiogenictherapy,hypoxia,andmetastasis:riskyliaisons,ornot? NatRevClinOncol, MolecularVision.ClinCancerRes, vol.20168, p.64966038873900393404, 2010.

D. Miles, N. Harbeck, and B. Escudier, Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials, Journal of Clinical Oncology, vol.29, issue.1, p.83, 2011.
DOI : 10.1200/JCO.2010.30.2794

L. Moserle and O. Casanovas, Antiangiogenesis and metastasis : a tumour and stromal cell alliance 108Schomber,Tetal.Differentialeffectsofthevascularendothelialgrowthfactorreceptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis, JInternMed. Mol CancerTher, vol.2738, p.1281375563, 2009.

S. Sathornsumetee, Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan, Journal of Clinical Oncology, vol.26, issue.2, pp.271-278, 2008.
DOI : 10.1200/JCO.2007.13.3652

R. Demir, L. Naschberger, and I. Demir, Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane, Pathology & Oncology Research, vol.428, issue.3, p.417422, 2009.
DOI : 10.1007/s12253-008-9140-y

O. Casanovas, D. Hicklin, D. Bergers, and D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late ?stage pancreatic islet tumors, Cancer, vol.8, p.299309, 2005.

E. Plimack, N. Tannir, E. Lin, B. Bekele, and E. Jonasch, Patterns of disease progression in metastaticrenalcellcarcinomapatientstreatedwithantivascularagentsandinterferon: impact of therapy on recurrence patterns and outcome measures, Cancer.Oncogene, vol.11531, pp.18591866-114, 2009.

B. Lima, L. Schoenfield, and A. Singh, The impact of intravitreal bevacizumab therapy on choroidalmelanomaBevacizumabandintraoculartumors:anintriguingparadoxBimodalmortalitydynamicsforuvealmelanoma:acue formetastasisdevelopmenttraits?, AmJOphtalmol.MolecularvisionBMCCancer.BenjaminLE:Tumorigenesisandtheangiogenicswitch.IntjRadiatOncolBiolPhys, vol.1511814339, issue.5, pp.323328-116, 1997.

S. Baillif, C. Maschi, P. Gastaud, and J. Caujolle, Intravitrealdexamethasone0.7mgimplantfor radiationmacularedemaafterprotonbeamtherapyforchoroidalmelanoma, 17841790 9. SERMENTD'HIPPOCRATE 9..SERMENTD'HIPPOCRATE EnprésencedesMaîtresdecettefaculté, Demescherscondisciplesetdevantl'effigied'Hippocrate, Jeprometsetjejured'êtrefidèleauxloisdel'honneur Etdelaprobitédansl'exercicedelamédecine, 2013.

. Etn, Admisàl'intérieurdesmaisons, Mesyeuxneverrontpascequ'ils'ypasse, Malanguetairalessecretsquimeserontconfiés Etmonétatneservirapasàcorromprelesmoeursniàfavoriserlecrime